MARLBOROUGH, Mass., July 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on Ju ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. CES, the world's largest annual consumer technology trade show, runs through January 12 and features about 4,000 exhibitors showing off their latest products and services to more than 130,000 attendees. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its pe ...

The latest trading session saw Boston Scientific (BSX) ending at $77.01, denoting a +0.01% adjustment from its last day's close. This change outpaced the S&P 500's 0.41% loss on the day. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 0.71%.The the stock of medical device manufacturer has risen by 2.67% in the past month, leading the Medical sector's gain of 1.74% and undershooting the S&P 500's gain of 3.53%.The investment community will be closely monitoring the performance of Bost ...

Boston Scientific, Inc. (BSX) recently obtained a CE Mark on the Vercise Neural Navigator 5 Software with STIMVIEW XT technology. When used as an element of the Vercise Genus Deep Brain Stimulation (DBS) Systems, it can provide clinicians with simple and actionable data for efficient programming to treat Parkinson’s disease, essential tremor and dystonia.The latest development comes as a significant boost for the company’s Neuromodulation business. In July 2023, the software had received the FDA’s approval. ...

U.S. markets continued to set all-time highs in June, with record-breaking stocks boosting major indices to new records last week. Even the traditionally slower DJIA logged two consecutive record peaks in two days.The market appears to favor the surge in artificial intelligence (AI) greatly as Nvidia (NASDAQ:NVDA), Microsoft (NASDAQ:MSFT) and Apple (NASDAQ:AAPL) battle for the highest market capitalization in the world. Such lofty heights in the market typically provoke fears of a correction, but pulling ba ...

In the latest trading session, Boston Scientific (BSX) closed at $76.71, marking a -1.29% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.31% for the day. Elsewhere, the Dow saw an upswing of 0.67%, while the tech-heavy Nasdaq depreciated by 1.09%.Shares of the medical device manufacturer witnessed a gain of 2.75% over the previous month, beating the performance of the Medical sector with its gain of 0.61% and the S&P 500's gain of 2.73%.Analysts and investors a ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific current ...

Boston Scientific (BSX) has announced plans to acquire carotid artery device specialist Silk Road Medical for approximately $1.26 billion. This is a strategic move poised to significantly expand the company’s cardiology portfolio.By paying $27.50 per share, Boston Scientific is offering a 38% premium over Silk Road's volume-weighted average share price over the past 60 days. With this transaction, expected to close in the second half of 2024, Silk Road will become a wholly owned subsidiary of the MedTech gi ...

The Zacks Medical – Products industry’s revenues are expected to continue its growth trajectory on the back of the recovery in demand for surgeries and procedures, new products and expansion into new markets. An earlier-than-expected demand for respiratory products is also boosting sales. The industry players are raising prices of their products and services to cope with the higher costs, thereby benefiting the top and bottom lines. However, the company continues to face challenges due to supply-chain const ...

The most recent trading session ended with Boston Scientific (BSX) standing at $76.31, reflecting a +0.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 0.25%. On the other hand, the Dow registered a gain of 0.15%, and the technology-centric Nasdaq increased by 0.03%.Coming into today, shares of the medical device manufacturer had gained 1.1% in the past month. In that same time, the Medical sector gained 0.11%, while the S&P 500 gained 3.34%.The upcoming earni ...